Y-27632 Dihydrochloride: Selective ROCK1/2 Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a highly selective inhibitor of Rho-associated protein kinases ROCK1 and ROCK2, with an IC₅₀ of ~140 nM for ROCK1 and a K_i of 300 nM for ROCK2, displaying over 200-fold selectivity versus related kinases (APExBIO). It disrupts Rho-mediated stress fiber formation and modulates cell cycle progression in a concentration-dependent manner (Linxweiler et al. 2018). The compound is soluble at ≥111.2 mg/mL in DMSO and ≥52.9 mg/mL in water, with improved solubility at 37°C. In preclinical models, Y-27632 reduces tumor invasion and enhances the viability of primary and stem cells. APExBIO’s A3008 formulation is widely used for cytoskeletal, cancer, and stem cell research due to its reproducibility and robust benchmark data.

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases central to actin cytoskeleton regulation, cell motility, and proliferation. Dysregulation of the Rho/ROCK signaling pathway contributes to cancer progression, metastasis, and aberrant cellular architecture. Inhibition of ROCK kinases has become a validated approach for dissecting cytoskeletal dynamics and cellular plasticity in both basic and translational research (Polyethyleniminelinear.com—this article details new in vivo benchmarks and model systems not covered in prior reviews). ROCK inhibitors like Y-27632 dihydrochloride are also critical for maintaining stem cell viability and for modulating cell cycle progression from G1 to S phase. This makes them indispensable in cancer models and regenerative medicine, where precise control of the cytoskeleton and cell proliferation is essential (Linxweiler et al. 2018).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride is a small-molecule, cell-permeable inhibitor that binds to the ATP-binding site of ROCK1 and ROCK2, thereby suppressing their kinase activity. The compound exhibits an IC₅₀ of approximately 140 nM for ROCK1, and a K_i of 300 nM for ROCK2, showing >200-fold selectivity against other kinases, including PKC, cAMP-dependent protein kinase, MLCK, and PAK (APExBIO). Inhibition of ROCK kinases prevents phosphorylation of downstream effectors such as myosin light chain (MLC), which in turn disrupts actin stress fiber formation and focal adhesion assembly. This leads to altered cell morphology, reduced contractility, and decreased cell migration. Y-27632 also impedes cytokinesis, resulting in cell cycle arrest at the G1/S transition. The compound’s high selectivity and rapid cellular uptake make it an effective tool for acute and chronic modulation of Rho/ROCK pathway dynamics (Biotin-11-ctp.com—this piece focuses on troubleshooting and protocol guidance, while the current article emphasizes quantitative selectivity and benchmark data).

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 activity with an IC₅₀ of 140 nM and ROCK2 with a K_i of 300 nM in kinase assays (APExBIO).
• The compound demonstrates >200-fold selectivity for ROCK1/2 over PKC, MLCK, PAK, and cAMP-dependent protein kinase in side-by-side kinase panels (APExBIO).
• Y-27632 suppresses Rho-mediated actin stress fiber formation in multiple cell lines, as shown by immunofluorescence and biochemical assays (Linxweiler et al. 2018).
• In 3D spheroid cultures derived from patient prostate cancer tissue, Y-27632 is used to maintain cellular viability and structure for several months (Linxweiler et al. 2018).
• In vivo, Y-27632 treatment reduces pathological structures, tumor invasion, and metastasis in mouse cancer models (cscc3.com—this article analyzes translational applications; this review adds specific solubility and storage parameters).
• Y-27632 is soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water, with solubility enhanced by warming to 37°C or using an ultrasonic bath (APExBIO).
• Stock solutions of Y-27632 can be stored at -20°C for several months; long-term storage of working solutions is not recommended (APExBIO).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is widely adopted for:

• Modulating actin cytoskeletal dynamics in cell biology and cancer research.
• Enhancing survival and expansion of dissociated stem cells in culture.
• Facilitating the formation and maintenance of primary 3D spheroid organoids from patient tissue (Linxweiler et al. 2018).
• Studying mechanisms of tumor invasion, metastasis, and cell motility.
• Inhibiting smooth muscle cell proliferation in prostatic and vascular models.

As602801.com discusses advanced disease modeling and endo-lysosomal applications, while this review prioritizes benchmarks for stem cell, cancer, and cytoskeletal studies with explicit solubility and selectivity data.

Common Pitfalls or Misconceptions

• Y-27632 dihydrochloride is not a pan-kinase inhibitor; it shows low activity toward PKC, MLCK, and PAK (selectivity >200x).
• It is not cytotoxic at standard doses (≤10 μM), but high concentrations (>100 μM) may cause off-target effects.
• The compound does not induce stemness; it only enhances viability by preventing dissociation-induced apoptosis.
• It is not effective for long-term storage in solution; stock solutions should be kept at -20°C and used within months.
• Y-27632's effects are reversible; removal from culture restores Rho/ROCK signaling and stress fiber formation.

Workflow Integration & Parameters

Y-27632 dihydrochloride is supplied as a solid by APExBIO (A3008) and should be stored desiccated at 4°C or below. For experimental use, prepare stock solutions in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), or water (≥52.9 mg/mL). Solubility can be improved by warming to 37°C or using an ultrasonic bath. Stock solutions are stable at -20°C for several months; avoid repeated freeze-thaw cycles. In cell culture, typical working concentrations range from 1–10 μM. For stem cell dissociation, 10 μM is standard. For inhibition of smooth muscle proliferation or cytoskeletal studies, concentrations should be titrated based on cell type and endpoint. In 3D spheroid culture, Y-27632 is added to modified stem cell medium to enhance cell viability and maintain tissue architecture (Linxweiler et al. 2018). For cancer metastasis models in vivo, dosing regimens should be optimized based on pharmacokinetic and toxicity data.

Conclusion & Outlook

Y-27632 dihydrochloride is a validated, highly selective ROCK1/2 inhibitor that enables precise modulation of the Rho/ROCK pathway in cell, tissue, and animal models. Its robust selectivity, solubility, and storage parameters make it an essential tool for cytoskeletal research, stem cell biology, and cancer studies. Ongoing research is extending its application in organoid modeling and translational disease systems. APExBIO’s A3008 formulation provides reproducible results across diverse workflows. For detailed protocols and batch-specific documentation, refer to the Y-27632 dihydrochloride product page.